Screening Epidemiological Program on Compensation Evaluation of Diabetes Mellitus Type 2 (DMT2) Patients on Oral Anti-diabetic (OAD) Monotherapy and Physicians Satisfaction of Their Usage

AstraZeneca

Status: Completed

Conditions: Type 2 Diabetes

Study type: Observational

Funder types: Industry

Identifiers

NCT01275794

NIS-CRU-ONG-2010/1

Details and patient eligibility

About

The purpose of the study is assessment of glycemic control and physicians satisfaction with results of DM2 OAD monotherapy

Enrollment: 1,849 patients

Sex: All

Ages: 35+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients have an established diagnosis of T2D
• Experience of therapy with one OAD during the from 6 months to 5 years before the registration in the Program

Exclusion criteria

• Experience of therapy with two or more OADs and/or insulin therapy and/or incretin mimetics (exenatide) at any time before registration in the Program
• Absence of changes in HbAc1 level during the last year before registration in the Program

Trial design

1,849 participants in 1 patient group

1

Description:

Patients have an established diagnosis of T2D, Age 35 years and more, Experience of therapy with one OAD during the from 6 months to 5 years before the registration in the Program